Table 1

Demographic and clinical characteristics of the SLE cohort and healthy individuals

CohortHealthy controlSLE (all)SLE NLR high*SLE NLR lowP value†
Number of individuals791416378
Age, median (range)48 (20–81)48 (20–81)45 (20–74)51 (20–81)0.27
Gender, % (female)878787871.00
Ethnicity, % (white)999696951.00
Disease duration,
median (range)
11 (0–46)12 (0–36)10 (0–46)0.59
SLEDAI, median (range)2 (0–18)2 (0–16)0 (0–18)0.10
SLEDAI (active)‡, %5667470.03
Immunosuppression§, %4860380.01
Hydroxychloroquine, %7373721.00
Prednisone 0 mg/day, %3319440.002
Prednisone 1–5 mg/day, %4456340.02
Prednisone 6–10 mg/day, %1619140.50
Prednisone >10 mg/day, %7681.00
Anti-dsDNA current, %1417120.34
Anti-dsDNA ever, %6173530.02
Nephritis current, %1110120.79
Nephritis ever, %3541290.16
  • Bold indicates statistically significant difference.

  • *NLR high is defined as above the 90th percentile of healthy individuals.

  • †Comparison between SLE NLR low and SLE NLR high using Mann-Whitney U test and Fisher’s exact test as applicable.

  • ‡Active disease was defined as SLEDAI >0.

  • §Immunosuppressive treatment includes azathioprine (n=32), mycophenolate (n=20), methotrexate (n=13), ciclosporin (n=2) and rituximab (n=2).

  • anti-dsDNA, antidouble-stranded DNA; NLR, neutrophil to lymphocyte ratio; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.